American Society of Hematology

Fig. 5.

$Fig. 5. FTI FPT III blocks Ras membrane translocation and Ras activation. / INA-6 cells were cultivated without IL-6 (lane 1), with 2 ng/mL IL-6 (lanes 2 and 3), or with BMSCs (lanes 4 and 5). U266 and INA-6 cells were treated with FTI FPT III (50 μM; lanes 3, 5, and 7) for 12 hours. (A) Western blot analysis of membrane fractions with an anti-Ras mAb was performed to analyze the effect of 50 μM FTI FPT III on membrane translocation of Ras. MHC class I served as a control for nonfarnesylated membrane proteins. (B) Activated Ras was precipitated with a Raf1-(RBD)-GST fusion protein and analyzed by using an anti-Ras antibody (Ras activation assay). Staining for Ras in whole cell lysates without precipitation served as a control. The IL-6–independent cell line U266 was cultivated without IL-6 or BMSCs (lanes 6 and 7).$

FTI FPT III blocks Ras membrane translocation and Ras activation.

INA-6 cells were cultivated without IL-6 (lane 1), with 2 ng/mL IL-6 (lanes 2 and 3), or with BMSCs (lanes 4 and 5). U266 and INA-6 cells were treated with FTI FPT III (50 μM; lanes 3, 5, and 7) for 12 hours. (A) Western blot analysis of membrane fractions with an anti-Ras mAb was performed to analyze the effect of 50 μM FTI FPT III on membrane translocation of Ras. MHC class I served as a control for nonfarnesylated membrane proteins. (B) Activated Ras was precipitated with a Raf1-(RBD)-GST fusion protein and analyzed by using an anti-Ras antibody (Ras activation assay). Staining for Ras in whole cell lysates without precipitation served as a control. The IL-6–independent cell line U266 was cultivated without IL-6 or BMSCs (lanes 6 and 7).

This Feature Is Available To Subscribers Only